Image pharmaphorum Editor Views & Analysis Steps to building a more patient-centric industry Lack of access, strict regulations, and demanding schedules have made it extremely difficult for patients to participate in clinical trials. Views & Analysis Three trends that will impact the life sciences industry in ... The life sciences industry has reached an inflection point as 2023 approaches. Views & Analysis How automation can help to address supply chain challenges i... Supply chain issues have been rife in pharmaceuticals for a while, but current socio-economic challenges such as the conflict in Ukraine and the COVID-19 pandemic have led to extended wait Views & Analysis Company profile: NeoImmuneTech Load more results
Views & Analysis Steps to building a more patient-centric industry Lack of access, strict regulations, and demanding schedules have made it extremely difficult for patients to participate in clinical trials.
Views & Analysis Three trends that will impact the life sciences industry in ... The life sciences industry has reached an inflection point as 2023 approaches.
Views & Analysis How automation can help to address supply chain challenges i... Supply chain issues have been rife in pharmaceuticals for a while, but current socio-economic challenges such as the conflict in Ukraine and the COVID-19 pandemic have led to extended wait
News Court sides with EU on decision to revoke Ocaliva's license Advanz Pharma's bid to keep its Ocaliva treatment for rare liver disease primary biliary cholangitis (PBC) on the EU market has ended in failure
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
